Ahmet Demirel

Dr. Ahmet Demirel

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
AGAli Kaan Güren
Ali Kaan Güren
ZBZilan Başkan
Zilan Başkan
ZGZeynep Ceren Balaban Genç
Zeynep Ceren Balaban Genç
TATuğçe Bulun Akyol
Tuğçe Bulun Akyol
EKErkam Kocaaslan
Erkam Kocaaslan
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
Background and Objectives: Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) offers significant advantages in terms of pathologic response and long-term survival; however, it is still unclear which patients will benefit the most from this treatment. This study aims to investigate the role of metabolic parameters on pretreatment positron emission tomography–computed tomography (PET/CT) images in predicting treatment response after TNT. Materials and Methods: The research was conducted using a single-center, retrospective design. Patients treated with total neoadjuvant therapy are included if they have locally advanced rectal cancer (cT3/T4-N0 or cTany-N1/N2). The patient group was categorized into two groups: CR and non-CR. Clinicopathologic features, PET/CT parameters, CA19-9, and CEA values were compared between these two groups. Results: In total, 52 patients were included. The CR group had 21 patients, and the non-CR group had 31 patients. The analysis demonstrated that the CR group had significantly lower metabolic tumor volume (MTV) and total lesion glycolysis (TLG) than the non-CR group (p = 0.022 vs. p = 0.003, p < 0.05). Also, CA19-9 values were lower than the non-CR group, and this difference was statistically remarkable (p = 0.40, p < 0.05). Conclusions: MTV and TLG parameters in PET/CT for pretreatment staging and pretreatment blood CA 19-9 levels are prognostic factors for predicting treatment response, and they may play a crucial role in choosing treatment. Comprehensive research is warranted on this subject with a larger patient population.

22 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BPBurak Paçacı
Burak Paçacı
EKErkam Kocaaslan
Erkam Kocaaslan
ADAhmet Demirel
Ahmet Demirel
FAFırat Akagündüz
Fırat Akagündüz
MTMustafa Alperen Tunç
Mustafa Alperen Tunç
NDNazım can Demircan
Nazım can Demircan
Background: Mucosal malignant melanoma (MMM) is a rare and aggressive malignancy with a dismal prognosis. While the Systemic Immune-Inflammation Index (SII) has emerged as a prognostic marker in various solid tumors, its specific value in MMM remains undefined. This study investigated the association between pretreatment SII and overall survival (OS) in patients with MMM. Methods: We retrospectively analyzed 106 adults with histologically confirmed MMM treated at six oncology centers in Turkey between 2005 and 2025. The baseline SII was calculated as platelet × neutrophil/lymphocyte counts obtained before definitive treatment. A receiver operating characteristic (ROC) analysis identified an optimal SII cutoff of 776 for overall survival (OS), defining low (<776) and high (≥776) SII groups. Results: Gastrointestinal and head and neck mucosa were the most frequent primary sites, and one-third of patients presented with metastatic disease. The median OS for the entire cohort was 23.3 months. Patients with a high versus low SII had a shorter OS (16.2 vs. 35.2 months; HR 2.71, 95% CI 1.67–4.40; p < 0.001). In multivariable analysis, a high SII (HR 1.88, 95% CI 1.12–3.14; p = 0.016), gastrointestinal primary site (HR 1.99, 95% CI 1.23–3.23; p = 0.005), and metastatic disease at diagnosis (HR 4.01, 95% CI 2.32–6.94; p < 0.001) independently predicted a worse OS. Conclusions: The SII is a novel, independent prognostic biomarker in MMM. Elevated pretreatment SII correlates with aggressive clinicopathologic features and inferior survival. As a readily accessible and cost-effective marker, SII may facilitate improved risk stratification in routine clinical practice for MMM patients.

2 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
EKErkam Kocaaslan
Erkam Kocaaslan
AGAli Kaan Güren
Ali Kaan Güren
FAFırat Akagündüz
Fırat Akagündüz
ADAhmet Demirel
Ahmet Demirel
MTMustafa Alperen Tunç
Mustafa Alperen Tunç
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
Background and Objectives: This study aimed to evaluate the prognostic impact of baseline body composition measurements and changes in muscle and adipose tissue during treatment on overall survival (OS) in metastatic non-small cell lung cancer (NSCLC) patients treated with nivolumab. Materials and Methods: Eighty-eight metastatic NSCLC patients who were initiated on nivolumab between January 2022 and December 2024 were retrospectively analyzed. Body composition parameters were derived from baseline and 3-month 18F-FDG PET/CT scans at the L3 level, including psoas muscle index (PMI), skeletal muscle index (SMI), intramuscular adipose content (IMAC), and subcutaneous fat density (SFD). Treatment-related changes in body composition were evaluated, and survival analyses were performed using Kaplan–Meier estimates and Cox regression models. Results: Overall, 34.1% (n = 30) of patients were classified as sarcopenic. Median OS was significantly longer in non-sarcopenic patients (19 months vs. 5 months, p < 0.001). In univariate analysis, older age, higher comorbidity burden, liver metastasis, baseline sarcopenia, and adverse treatment-related changes in muscle and nutritional parameters were found to be associated with OS. In multivariate analysis, only unfavorable changes in skeletal muscle (ΔSMI; HR 3.39, p = 0.003) and subcutaneous fat radiodensity (ΔSFD; HR 2.45, p = 0.02) remained independent adverse prognostic factors. Baseline body composition parameters did not maintain their independence in multivariate models. Conclusions: Our study demonstrates that muscle loss or insufficient gain and unfavorable changes in subcutaneous fat radiodensity during nivolumab treatment more strongly predict overall survival compared to baseline measurements. These findings highlight the clinical importance of monitoring dynamic body composition throughout treatment, rather than static assessments, in NSCLC patients receiving immunotherapy.

19 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EKErkam Kocaaslan
Erkam Kocaaslan
AGAli Kaan Güren
Ali Kaan Güren
FAFırat Akagündüz
Fırat Akagündüz
ADAhmet Demirel
Ahmet Demirel
MTMustafa Alperen Tunç
Mustafa Alperen Tunç
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
Background/Objectives: This study aimed to evaluate the prognostic value of 18F-FDG PET/CT-based secondary lymphoid organ metabolic ratios—spleen/liver (SLR), bone marrow/liver (BLR), and ileocecal region/liver (ILR)—and hematological inflammation markers (neutrophil/lymphocyte ratio [NLR] and systemic immune-inflammation index [SII]) obtained before nivolumab treatment in relation to survival in patients with advanced non-small cell lung cancer (NSCLC). Methods: This retrospective single-center study included 79 advanced NSCLC patients who were treated with nivolumab monotherapy at Marmara University Faculty of Medicine Hospital between 2022 and 2024. Pretreatment SLR, BLR, and ILR ratios were calculated from 18F-FDG PET/CT examinations; NLR and SII values were obtained from hematological data. Survival outcomes were analyzed using the Kaplan–Meier method, and prognostic factors were assessed using Cox proportional hazards regression analysis. In a subset of patients, an exploratory longitudinal analysis was performed using early follow-up PET/CT to assess follow-up-to-baseline changes in immune-organ metabolic ratios in relation to overall survival. Results: High NLR and SII levels were significantly associated with shorter progression-free survival and overall survival. In contrast, no significant associations were observed between PET/CT-derived metabolic ratios (SLR, BLR, and ILR) and survival. Multivariate analysis identified the presence of liver metastases and a high NLR as independent adverse prognostic factors for overall survival. Conclusions: In this homogeneous real-world cohort treated exclusively with single-agent nivolumab, PET/CT-derived secondary lymphoid organ metabolic ratios showed limited prognostic value at baseline and during early on-treatment assessment. In contrast, hematological inflammation markers, especially high NLR levels, are strong prognostic indicators of survival and may complement established clinical factors in risk stratification.

Verified
Journal Article
Open access
PDF file
MTMustafa Alperen Tunç
Mustafa Alperen Tunç
AGAli Kaan Güren
Ali Kaan Güren
BPBurak Paçacı
Burak Paçacı
FAFırat Akagündüz
Fırat Akagündüz
EKErkam Kocaaslan
Erkam Kocaaslan
MSMurat Sarı
Murat Sarı
Background: Adjuvant therapy decisions for T3N0 stage II colon cancer remain controversial. This study evaluates long-term outcomes, recurrence patterns, and conditional relapse-free survival (RFS) in pathologic T3N0 colon cancer. Methods: This retrospective study included 306 patients undergoing curative resection for T3N0 colonic adenocarcinoma (1995–2020). Early recurrence was defined as recurrence or death within 3 years after surgery. Survival was estimated via Kaplan–Meier. Cox regression, adjusted for treatment eras, evaluated survival factors. Inverse Probability of Treatment Weighting (IPTW) minimized selection bias. Conditional RFS utilized a 5-year landmark analysis. Results: Over a 133-month median follow-up, 72 patients (23.5%) recurred. Most recurrences (81.9%) occurred within 3 years; only 9.7% after 5 years. Five- and 10-year OS rates were 80.9% and 70.4%. Inadequate lymph node dissection (<12 nodes) was performed in 29.7% of the entire cohort and was found to be an independent adverse prognostic factor for OS. Adjuvant chemotherapy lacked overall OS benefit, though IPTW analysis suggested potential benefit in patients with inadequate dissection. Conditional RFS (5–10 years) for patients recurrence-free at 60 months was 95.0%. Exploratory analyses showed descriptive differences in post-relapse survival based on the clinical triggers prompting radiological evaluation (marker-triggered versus symptom-triggered presentations). Conclusions: T3N0 colon cancer recurrences occur predominantly within the first 3–5 years after surgery. Inadequate lymph node dissection is the primary adverse prognostic factor. Although a 5-year follow-up period appears adequate for most patients, individualized extended surveillance may be considered for selected high-risk patients. Adjuvant treatment and follow-up strategies should be tailored according to surgical quality and risk factors.

24 September 2026 in Medicina
Verified
Journal Article
Open access
PDF file
AÇAbdussamet Çelebi
Abdussamet Çelebi
EMEren Meral
Eren Meral
FAFırat Akagündüz
Fırat Akagündüz
ADAhmet Demirel
Ahmet Demirel
MTMustafa Alperen Tunç
Mustafa Alperen Tunç
MSMurat Sarı
Murat Sarı
Background and Objectives: This study aimed to validate the prognostic value of clinicopathologic risk factors and assess the discriminatory performance of a guideline-based seven-factor risk stratification system in T3N0 colon cancer. Secondary objectives included examining the independent prognostic role of mucinous histology and analyzing current adjuvant chemotherapy decision-making patterns. Materials and Methods: A total of 174 patients who underwent curative resection between 2015 and 2025 and were diagnosed with pathologic T3N0M0 (stage IIA) colon adenocarcinoma were retrospectively reviewed. Patients with T4 disease, rectal tumors, synchronous malignancies, neoadjuvant therapy and mismatch repair deficiency (dMMR/MSI-H) were excluded. Seven high-risk factors were defined: lymphovascular invasion (LVI), perineural invasion (PNI), intestinal obstruction, perforation, inadequate lymph node sampling (<12 lymph nodes), poor differentiation (Grade 3 and 4), and high-grade tumor budding (BD3, ≥10 buds according to ITBCC criteria). Mucinous histology was evaluated as a separate subgroup analysis. The primary endpoint was recurrence-free survival (RFS); secondary endpoints were disease-free survival (DFS) and overall survival (OS). Competing risks analysis was performed using the Aalen–Johansen estimator, with death without recurrence as the competing event. Results: The median follow-up was 43.7 months. Five-year RFS rates were 97.1%, 92.8%, and 70.0% in the low-, intermediate-, and high-risk groups, respectively (log-rank p = 0.041). Five-year OS rates were 87.2%, 88.6%, and 69.9%, respectively (log-rank p = 0.0004). Five-year cumulative incidence of recurrence in competing risks analysis was 2.9%, 7.1%, and 26.0%, respectively. Five-year DFS rates were 87.2%, 83.1%, and 54.2% (log-rank p = 0.0003). In multivariate DFS analysis, intestinal obstruction (HR = 4.26; 95% CI: 2.05–8.87; p < 0.001) and tumor budding (HR = 3.77; 95% CI: 1.67–8.53; p = 0.001) were independent prognostic factors; consistent but exploratory RFS estimates were observed (obstruction HR = 8.51; 95% CI: 2.50–28.96; p = 0.001; tumor budding HR = 5.48; 95% CI: 1.72–17.44; p = 0.004), derived from 12 recurrence events and therefore prone to overfitting. As a continuous variable, each 1-unit increase in the seven-factor risk score increased the RFS hazard 1.74-fold (95% CI: 1.21–2.51; p = 0.003; RFS C-index = 0.656; 95% CI: 0.489–0.830). A parsimonious two-factor model (obstruction + tumor budding) achieved a higher C-index of 0.760 (95% CI: 0.569–0.921) for RFS. Mucinous histology was present in 17 patients (9.8%) and showed no recurrence events. Adjuvant CT rates increased significantly with higher risk scores (p = 0.002). Conclusions: Guideline-based seven-factor risk stratification demonstrates statistically significant, though modest, discriminatory performance (RFS C-index = 0.656; 95% CI: 0.489–0.830; DFS C-index = 0.646; 95% CI: 0.519–0.778) in pMMR T3N0 colon cancer. Intestinal obstruction and tumor budding are independent prognostic factors that effectively stratify patients by recurrence risk; a parsimonious two-factor model based on these two features matched or exceeded the discrimination of the full score. The seven-factor system should be regarded as a validation of guideline-defined high-risk features that may support adjuvant chemotherapy discussions in stage IIA colon cancer; external validation is required before clinical implementation.